Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug interactions and pharmacokinetics news

Show

From To
Viral Load Reductions Persist With Less Efavirenz for HIV

The virologic responses with reduced-dose efavirenz at 48 weeks have proven durable out to 96 weeks, ENCORE1 study results show.

Published
07 November 2014
From
Medscape (requires free registration)
Efavirenz compromises hormonal contraceptive implant

The widely prescribed non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz substantially reduces levels of the hormonal contraceptive levonorgestrel, a component of a progesterone contraceptive implant widely used in

Published
03 November 2014
By
Keith Alcorn
Change to recommended regimen for post-exposure prophylaxis (PEP)

The Expert Advisory Group on AIDS (EAGA) has recommended a change in the recommended regimen for post-exposure prophylaxis from tenofovir/emtricitabine with Kaletra to tenofovir/emtricitabine with raltegravir.

Published
11 September 2014
From
Expert Advisory Group on AIDS (EAGA)
Dosage of HIV drug may be ineffective for half of African-Americans

Many African-Americans may not be getting effective doses of the HIV drug maraviroc. The initial dosing studies included mostly European-Americans, who generally lack a protein that is key to removing maraviroc from the body, resulting in higher concentrations of the drug in the blood. The current study shows that people with maximum levels of the protein CYP3A5 -- including nearly half of African-Americans -- end up with lower levels of maraviroc in their bodies.

Published
28 August 2014
From
Eurekalert Medicine & Health
Opioid Therapy No Bar to Novel HCV Drugs

People on opioid substitution therapy for drug addiction can be safely and effectively treated for hepatitis C (HCV) with an investigational combination of medications, researchers said here.

Published
24 July 2014
From
MedPage Today
Advice on Best ART Regimen for Patients Taking Cancer Therapy

Because no clinical trials address the question and published data are insufficient to support guidelines, the optimal antiretroviral therapy (ART) regimen for patients undergoing cancer chemotherapy remains unknown. But experts from Houston’s M.D. Anderson Cancer Center offer suggestions to help clinicians individualize therapy for each patient.

Published
25 June 2014
From
International AIDS Society
In HIV/TB coinfection, raltegravir may be an alternative to efavirenz

Patients coinfected with HIV and tuberculosis (TB) may benefit from raltegravir as an alternative to efavirenz, new research suggests.

Published
02 June 2014
From
Medscape
No critical interactions between ledipasvirsofosbuvir and certain key antiretrovirals

Ledipasvir/sofosbuvir, a fixed-dose coformulation of two direct-acting antivirals (DAAs) for HCV infection, did not have a clinically significant impact on five frequently used antiretrovirals--raltegravir, efavirenz, rilpivirine, and tenofovir/emtricitabine (TDF/FTC)--according to results of three studies in healthy volunteers.

Published
29 May 2014
From
NATAP
Calcium and Iron Supplements Lower Dolutegravir Levels When Taken Between Meals

Calcium supplements taken with dolutegravir between meals lowered dolutegravir exposure by one third. Iron supplements with dolutegravir between meals approximately halved dolutegravir exposure. Supplements did not have this effect when taken with dolutegravir with a meal, or when dolutegravir was taken 2 hours before the supplement.

Published
24 May 2014
From
NATAP
Better Late Than Never: Efavirenz Dose Optimization

After a study suggests that we’ve been using too high a dose of efavirenz for a decade and a half, the move toward scaling up a lower and more cost-effective one faces some hurdles.

Published
03 April 2014
From
Treatment Action Group
← First12345...18Next →

Filter by country